Cannabidiol has been indicated mainly in the treatment of neurological and psychiatric diseases. The indication of use, dosages, and duration of treatment must be defined by a physician with active registration at CFM.

According to RDC 327/2019, the indication and method of use of Cannabis products are the responsibility of the attending physician.

Any physician with an active registration at CFM can prescribe Cannabis products in Brazil using a Type B (blue) prescription. The indication of use, dosages, and treatment duration must be informed to the patient during prescription.

Pharmacological safety tests, acute toxicity, and genotoxicity have been concluded and attest to its safety. The tests are available in the medical area.

Gastrointestinal adverse events such as nausea, diarrhea, or constipation, loss of appetite, and gastric intolerance are the most common. Drowsiness, lethargy, dizziness, sedation, and fatigue have also been described in scientific literature associated with cannabidiol use. When present, adverse effects are usually mild or moderate. In case of adverse reactions or any changes, the prescribing physician should be consulted and product use discontinued.

The product does not contain artificial flavorings or scentings and has no taste or smell.